IN2014DN08964A - - Google Patents
Info
- Publication number
- IN2014DN08964A IN2014DN08964A IN8964DEN2014A IN2014DN08964A IN 2014DN08964 A IN2014DN08964 A IN 2014DN08964A IN 8964DEN2014 A IN8964DEN2014 A IN 8964DEN2014A IN 2014DN08964 A IN2014DN08964 A IN 2014DN08964A
- Authority
- IN
- India
- Prior art keywords
- cells
- diseases
- specific regulatory
- antigen specific
- suppressing
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 abstract 4
- 210000003289 regulatory T cell Anatomy 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 230000001640 apoptogenic effect Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010052779 Transplant rejections Diseases 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000001461 cytolytic effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261640537P | 2012-04-30 | 2012-04-30 | |
PCT/EP2013/058835 WO2013164289A1 (fr) | 2012-04-30 | 2013-04-29 | Procédés d'induction de lymphocytes t régulateurs spécifiques d'un antigène |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN08964A true IN2014DN08964A (fr) | 2015-05-22 |
Family
ID=48483027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN8964DEN2014 IN2014DN08964A (fr) | 2012-04-30 | 2013-04-29 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150125880A1 (fr) |
EP (1) | EP2844741A1 (fr) |
JP (1) | JP2015518376A (fr) |
KR (1) | KR20150028225A (fr) |
CN (1) | CN104411818A (fr) |
AU (1) | AU2013255888A1 (fr) |
BR (1) | BR112014026606A2 (fr) |
CA (1) | CA2871541A1 (fr) |
HK (1) | HK1206786A1 (fr) |
IN (1) | IN2014DN08964A (fr) |
RU (1) | RU2014148172A (fr) |
WO (1) | WO2013164289A1 (fr) |
ZA (1) | ZA201407298B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2540255B1 (es) * | 2013-11-19 | 2016-05-12 | Tomás SEGURA MARTÍN | Método de aislamiento de cuerpos apoptóticos |
GB201418433D0 (en) * | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
KR20220132023A (ko) * | 2016-04-19 | 2022-09-29 | 임시스 에스에이 | 신규 면역원성 CD1d 결합 펩티드 |
EP3600378A4 (fr) * | 2017-03-24 | 2020-12-23 | Orpheus Bioscience Inc. | Pantids pour le traitement de troubles auto-immuns |
CN112469826B (zh) * | 2018-04-27 | 2024-02-09 | (株)爱恩德生物 | 通过磁珠附着至细胞进行的基于磁性的生物淘选方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2926004A1 (fr) * | 2006-08-11 | 2008-02-14 | Life Sciences Research Partners Vzw | Peptides immunogeniques et leurs utilisations pour les troubles allergiques et autoimmuns |
ES2650236T3 (es) | 2008-02-14 | 2018-01-17 | Life Sciences Research Partners Vzw | Linfocitos T CD4+ con propiedades citolíticas |
ES2626115T3 (es) | 2008-02-14 | 2017-07-24 | Life Sciences Research Partners Vzw | Péptidos inmunogénicos y su uso en trasplante |
-
2013
- 2013-04-29 WO PCT/EP2013/058835 patent/WO2013164289A1/fr active Application Filing
- 2013-04-29 BR BR112014026606A patent/BR112014026606A2/pt not_active IP Right Cessation
- 2013-04-29 RU RU2014148172A patent/RU2014148172A/ru not_active Application Discontinuation
- 2013-04-29 AU AU2013255888A patent/AU2013255888A1/en not_active Abandoned
- 2013-04-29 CA CA2871541A patent/CA2871541A1/fr not_active Abandoned
- 2013-04-29 IN IN8964DEN2014 patent/IN2014DN08964A/en unknown
- 2013-04-29 KR KR1020147030054A patent/KR20150028225A/ko not_active Application Discontinuation
- 2013-04-29 US US14/397,560 patent/US20150125880A1/en not_active Abandoned
- 2013-04-29 CN CN201380022688.7A patent/CN104411818A/zh active Pending
- 2013-04-29 JP JP2015509392A patent/JP2015518376A/ja active Pending
- 2013-04-29 EP EP13724528.8A patent/EP2844741A1/fr not_active Withdrawn
-
2014
- 2014-10-08 ZA ZA2014/07298A patent/ZA201407298B/en unknown
-
2015
- 2015-08-04 HK HK15107486.9A patent/HK1206786A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2015518376A (ja) | 2015-07-02 |
WO2013164289A1 (fr) | 2013-11-07 |
HK1206786A1 (en) | 2016-01-15 |
EP2844741A1 (fr) | 2015-03-11 |
US20150125880A1 (en) | 2015-05-07 |
CA2871541A1 (fr) | 2013-11-07 |
AU2013255888A1 (en) | 2014-10-23 |
BR112014026606A2 (pt) | 2017-07-18 |
CN104411818A (zh) | 2015-03-11 |
KR20150028225A (ko) | 2015-03-13 |
ZA201407298B (en) | 2016-02-24 |
RU2014148172A (ru) | 2016-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019014009A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
MX2019014960A (es) | Composiciones de fosfodiesterasa de tipo 5 (pde5) y métodos de inmunoterapia. | |
IL280743B (en) | Methods for enriching and producing immune cell populations for stress treatment | |
PH12017500803A1 (en) | Anti-pd-1 antibodies | |
IL253879A0 (en) | Methods for engineering allogeneic t cells to increase continuity and/or insertion into patients | |
MX2019000180A (es) | Composiciones de células t para la inmunoterapia. | |
MX2022003698A (es) | Composiciones de nanoparticulas y metodos para inmunoterapia. | |
WO2015154012A8 (fr) | Populations de cellules tueuses naturelles (nk) clonogéniques et procédés de production et d'utilisation de telles populations | |
EP3122181A4 (fr) | Compositions et procédés pour expansion ex vivo des cellules souches hématopoïétiques humaines | |
EA201391601A1 (ru) | Наноносители, вызывающие иммунную толерантность, для снижения ответной реакции цитотоксических т-лимфоцитов | |
MY185016A (en) | Progenitor cells of mesodermal lineage | |
IN2014CN03892A (fr) | ||
TN2011000174A1 (en) | Compounds that expand hematopoietic stem cells | |
EA201290876A1 (ru) | Композиции индуцированных дендритных клеток и их использование | |
MX339533B (es) | Composiciones y metodos de daclizumab (dac) del proceso de alto rendimiento (hyp). | |
IN2014DN08964A (fr) | ||
IN2015DN00263A (fr) | ||
WO2014134084A3 (fr) | Compositions de phf20 et jmjd3 et méthodes d'utilisation pour l'immunothérapie anticancéreuse | |
PT2700708T (pt) | Intensificação da capacidade estimuladora de células t de células apresentadoras de antigénios humanas in vitro e in vivo e sua utilização em vacinação | |
MX2020005849A (es) | Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos. | |
PH12019502036A1 (en) | Peptides and methods for the treatment of diabetes | |
CO2020006855A2 (es) | Composiciones y métodos para el agotamiento de células cd2+ | |
MX2013011421A (es) | Derivados de pirazolo-pirimidina. | |
MX2015017959A (es) | Composiciones y metodos para inmunoterapia. | |
MX356163B (es) | Anilinas sustituidas como antagonistas de ccr(4). |